{"id":"W4200501854","doi":"10.1158/1535-7163.targ-21-p230","title":"Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"T790M; Osimertinib; Medicine; Epidermal growth factor receptor; Exon; Cancer research; EGFR inhibitors; Mutant; Lung cancer; Mutation; Gefitinib; Cancer; Oncology; Internal medicine; Erlotinib; Gene; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006284359,0.0003134492,0.0005753165,0.0001537863,0.00007315182,0.00001950085,0.00008147125,0.00009524463,0.00003023687],"category_scores_gemma":[0.00001111599,0.0002638174,0.00008055141,0.0005737906,0.00008270802,0.00008938388,0.00003199301,0.0002296421,3.459436e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005090107,"about_ca_system_score_gemma":0.0009761858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001020218,"about_ca_topic_score_gemma":0.001065809,"domain_scores_codex":[0.9980736,0.00008656908,0.0005640954,0.0004970041,0.0004600534,0.0003187026],"domain_scores_gemma":[0.9983577,0.00005719268,0.0003650252,0.0003003687,0.0007963988,0.0001233279],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004365435,0.01287223,0.6411853,0.001368188,0.003550968,0.0002715445,0.02250669,0.0003984149,0.3062664,0.00002302438,0.00006236457,0.007129463],"study_design_scores_gemma":[0.03919671,0.002132316,0.475951,0.001176335,0.002213709,0.000002384351,0.00224195,0.0001170907,0.4762774,0.00001889927,0.00016903,0.0005031117],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924399,0.004528768,0.0002363444,0.000350078,0.0001231472,0.001724186,0.0004640191,0.0000166764,0.0001168344],"genre_scores_gemma":[0.9980251,0.000412351,0.000686608,0.0003290464,0.00003286663,0.0002970664,0.00008090747,0.00006291329,0.00007311724],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.170011,"threshold_uncertainty_score":0.9999814,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0105822064170465,"score_gpt":0.289737410597893,"score_spread":0.2791552041808465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}